Savara Q1 2026 Earnings Report

Savara EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.14
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Savara Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.50 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Savara Announcement Details

• Quarter: Q1 2026
• Date: 5/12/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, May 13, 2026
• Conference Call Time: 4:00PM ET

Savara (NASDAQ:SVRA) (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant. In addition, Savara has in-licensed Brensocatib, a dipeptidyl peptidase 1 (DPP-1) inhibitor originally developed by AstraZeneca, which is being evaluated in clinical trials for non-cystic fibrosis bronchiectasis (NCFBE) and nontuberculous mycobacterial (NTM) lung infections. These programs reflect the company’s strategy of leveraging existing pharmacological data to streamline development in orphan respiratory indications.

Founded in 2013 and headquartered in Austin, Texas, Savara conducts its research and development activities primarily in North America and Europe. The company collaborates with academic institutions, patient advocacy groups and strategic partners to support clinical trial execution, regulatory interactions and eventual commercialization planning. Savara’s management team brings together expertise in drug development, regulatory affairs and respiratory medicine, all aimed at transforming care for patients with life-threatening pulmonary disorders.